Advanced Magnetic Resonance Imaging Technology Suggests Axonal Repair in Multiple Sclerosis Patients Treated with COPAXONE(R)

JERUSALEM, Jan, 2012 (BUSINESS WIRE) -- Researchers utilizing an advanced magnetic resonance imaging (MRI) technology to characterize and chart the evolution of MS lesions found that relapsing-remitting multiple sclerosis (RRMS) patients treated with COPAXONE(R) (glatiramer acetate injection) experienced significantly increased magnetization transfer ratio (MTR). Magnetization transfer ratio is a nonconventional MRI technique used to investigate abnormalities in brain structures, and increased values indicate potential remyelination and axonal tissue repair. 

The 12-month MRI study, conducted at the Buffalo Neuroimaging Analysis Center (BNAC) located in the Jacobs Neurological Institute at the University at Buffalo, State University of New York, examined 40 RRMS COPAXONE(R) naive patients. Patients received monotherapy with COPAXONE(R) (20 mg/day) everyday beginning at the baseline visit for 12 months. Study patients were assessed at baseline and after 12 months based on clinical examinations and using detailed conventional and nonconventional MRI protocols, including magnetization transfer imaging (MTI), an emerging MRI technique used to assess remyelination in the brains of MS patients. 

"These data indicate that treatment with COPAXONE(R) resulted in a measureable amount of tissue repair in study patients," said Robert Zivadinov, MD, PhD, Director of the BNAC, Professor of Neurology at the University at Buffalo, and lead study author. "The observed increases in MTR point to a potential for remyelination. Overall, these findings contribute to the vast body of research that supports the long-term efficacy and safety of the therapy." 

source: MarketWatch

No comments: